ABIVAX: 2016 Financial Calendar

Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced its financial reporting schedule for 2016.

Financial publications will be issued after the market close. This schedule is indicative and subject to change.

• Half-year report on the liquidity contract: January 7, 2016
• 2016 Full-year Results: March 15, 2016
• Publication of the 2016 Financial Annual Report: April 28, 2016
• Annual General Meeting: June 24, 2016
• Half-year report on the liquidity contract: July 7, 2016
• 2016 Half-year Results: September 20, 2016
• Publication of the 2016 Financial Half-Year Report: September 28, 2016

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20151210005623/en/